Isofol MedicalWaiting for initiation of phase III
The Q2 report was a non-event, as is usually the case for biotech companies in the development phase. The next potential catalyst will be the FDA’s approval of the company’s special protocol agreement (SPA) and subsequent initiation of the phase III trial, ISO-CC-007, in October. We have not made any changes to our forecasts and reiterate our fair value of SEK18–49.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.